Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of an investigational yellow fever vaccine called vYF in young children aged 9 months to 5 years. This Phase III study compares vYF with two licensed yellow fever vaccines, Stamaril and YF-VAX, including when vYF is given alongside the measles, mumps, and rubella MMR vaccine in infants aged 11 to 15 months. The study aims to see if vYF can safely help the body develop protective antibodies against yellow fever. Participants will be randomized into groups by age to receive one dose of either vYF, Stamaril, or YF-VAX vaccine. A special group of infants aged 11 to 15 months will receive vYF together with the MMR vaccine in one visit. A subset of children aged 9 to 24 months will be invited to receive a booster dose of the yellow fever vaccine three years after the initial vaccination. The booster is not offered to the group receiving the combined vYF and MMR vaccine. Participants will be involved for about three years, with some in the booster group followed for an additional six months. The study includes multiple blood tests to measure immune response at several time points, starting from the day of vaccination and continuing annually up to three years. Safety is monitored closely through reports of side effects and laboratory tests. The main outcome is the percentage of participants developing antibodies against yellow fever 28 days after vaccination.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating two dose levels of mRNA-1283 in children aged 6 months to less than 12 years to find the best dose for each age group. The study is a phase 2, randomized, observer-blind trial comparing mRNA-1283 with mRNA-1273 as an active comparator. It aims to assess safety, immune response, and side effects related to these vaccines against SARS-CoV-2. The study includes two cohorts Cohort 1 involves children aged 2 to less than 12 years receiving a single intramuscular dose of either mRNA-1283 at Dose Level 1 or Dose Level 2, or mRNA-1273. Cohort 2 includes children aged 6 months to less than 2 years who are unvaccinated against COVID-19 and receive two intramuscular doses 28 days apart of either mRNA-1283 at Dose Level 1 or Dose Level 2, or mRNA-1273. The study compares the immune responses and side effects between these groups. Participants will be monitored for local and systemic adverse reactions for 7 days after vaccination and unsolicited adverse events for up to 28 days. Serious and medically attended adverse events will be tracked throughout the study, which lasts up to 13 months. Researchers will measure antibody levels against SARS-CoV-2 at specific visits to evaluate immune response. The trial includes regular medical evaluations and safety assessments to ensure participant well-being.